Vera Bril
Co-Applicant
Professor of Neurology at University of Toronto | Neurologist and Director of the Neuromuscular Section at University Health Network and the University of Toronto
Senior Scientist at the Toronto General Research Institute
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Biography
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She directs the Ellen & Martin Prossserman Centre for Neuromuscular Diseases at the University Health Network, and the Prosserman Family Neuromuscular Clinic and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy leading to publication of more than 350 journal articles.
Recent Publications
Alcantara, M, Mannan, S, de la Cruz, J, Bril, V. Value of multi-modality small fiber assessments in a genotypically diverse cohort of transthyretin-related amyloidosis in the early stages of disease. Med Clin (Barc). 2024. PMID:38616431
Hébert, J, De Santis, RJ, Daniyal, L, Mannan, S, Ng, E, Thain, E et al.. Epilepsy in neurofibromatosis type 1: Prevalence, phenotype, and genotype in adults. Epilepsy Res. 2024.202 107336 PMID:38471245
Howard, JF Jr, Bril, V, Vu, T, Karam, C, Peric, S, De Bleecker, JL et al.. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023.14 1284444 PMID:38318236
Antozzi, C, Guptill, J, Bril, V, Gamez, J, Meuth, SG, Nowak, RJ et al.. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study. Neurology. 2024.102 (2)e207937 PMID:38165333
Matic, A, Alfaidi, N, Bril, V. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis. Expert Opin Biol Ther. 2023.23 (12)1163-1171 PMID:38099334
Nowak, RJ, Breiner, A, Bril, V, Allen, JA, Khan, S, Levine, T et al.. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension. Ann Clin Transl Neurol. 2024.11 (1)194-206 PMID:38062618
Martinez-Harms, R, Barnett, C, Alcantara, M, Bril, V. Reply to letter in response to Rethinking the diagnosis of double-seronegative myasthenia gravis. Eur J Neurol. 2024.31 (3)e16152 PMID:37991152
Lanctôt, SO, Lovblom, LE, Lewis, EJH, Morris, M, Cardinez, N, Scarr, D et al.. Fasted C-Peptide Distribution and Associated Clinical Factors in Adults With Longstanding Type 1 Diabetes: Analysis of the Canadian Study of Longevity in Type 1 Diabetes. Can J Diabetes. 2024.48 (2)89-96 PMID:37944665
Bril, V, Howard, JF Jr, Karam, C, De Bleecker, JL, Murai, H, Utsugisawa, K et al.. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. Eur J Neurol. 2024.31 (1)e16098 PMID:37843174
Abraham, A, Fainmesser, Y, Drory, VE, Bril, V. Quantitative sonographic assessment of muscle thickness and fasciculations distribution is a sensitive tool for neuromuscular disorders. PLoS One. 2023.18 (9)e0292123 PMID:37768998
See more on PubMed